

Open Access

Original Article

Low Dose Prophylaxis (LDP) in Haemophilia- by Using Extended Half- Life (EHL) Factor Concentrates

Tahira Zafar¹, Lubna Zafar¹,
Arshad Rabbani², Raan Zeeshan¹,
Asma Nafisa³, Sundas Durrani³
Nadeem Ikram³

¹Haemophilia Treatment Centre,
Haemophilia Patients' Welfare Society,
Rawalpindi;

²Department of Medicine, Benazir Bhutto
Hospital, Rawalpindi

³Department of Pathology, Benazir Bhutto
Hospital, Rawalpindi

Abstract

Objective: To assess the effectiveness of low dose prophylaxis in Haemophilia, as compared to episodic treatment

Methodology: In this prospective cohort study 21 patients with severe Haemophilia A, registered with Haemophilia Treatment Centre Rawalpindi, were enrolled. According to Low Dose Prophylaxis (LDP) protocol, patients were started on a uniform dose of extended half life (EHL), recombinant, Factor VIII concentrate (Eloctate), 250 IU, intravenous, once weekly, escalated to twice weekly if a patient experienced more than two spontaneous bleeds in three months, and thrice weekly if bleeding continued after initial dose escalation. Twenty one patients, receiving episodic treatment (treatment as per requirement of bleeding episode) were also included. Primary outcome was the total spontaneous bleeds. Secondary outcome was presence of factor VIII inhibitors. All the patients were assessed every four months for spontaneous bleeds. Inhibitors were screened in serum six monthly. Patients were followed for twenty four months and Annualized Bleeding Rate (ABR) was calculated.

Results: Eleven patients were on once weekly, nine on twice weekly and one thrice weekly infusions. Age range was two to nine years (mean 4.07 years). Low dose prophylaxis dose per Kg of body weight per week was calculated by multiplying the number of times the dose was given in a week with 250 IU and the result divided by the body weight in Kg. Mean Annualized Bleeding Rate (ABR), during study period was 0.07, which is significantly less as compared to episodic treatment group ($p < 0.001$). Development of inhibitors was not found in any patient on prophylactic treatment. In prophylactic group majority (91.66%) did not showed any bleeding episode during treatment period.

Conclusion: Low Dose prophylaxis significantly reduces Annualized bleeding Rate (ABR) and production of inhibitors, as compared to those who are on episodic treatment.

Key Words: Haemophilia, Low Dose Prophylaxis, Extended Half- Life Factor Concentrates, Inhibitors, Annualized Bleeding Rate

Address for Correspondence

Dr Nadeem Ikram

drnadeemikram@gmail.com

Introduction

Approximately 400,000 people globally are affected by haemophilia, and only 25% receive adequate treatment.¹ The key to a successful long-term outcome in patients with haemophilia is an efficient prophylaxis that prevents bleeding in joints. Prophylactic therapy is given in developed countries from the last two decades. On the contrary, episodic therapy (ET) is still the mode of treatment in middle- and low-income countries.²⁻⁴ In developing and underdeveloped countries the freedom to adjust the determinants of management are impaired by lack of resources and affordable products. Without prophylaxis haemophilics suffer tremendous disability, leaving them with crippling arthropathy, and unable to integrate fully to society. Many become wheel-chair

bound, unable to attend school or secure gainful employment.⁵

Efficient prophylaxis requires taking into account the available resources (clotting factor concentrate type, trough levels, etc), the bleeding trigger (activity level, chronic synovitis, already existing arthropathy, etc) and most importantly the number of acceptable bleeds, especially joint bleeds. In an ideal setting the number of spontaneous bleeds should be minimized in order to prevent the manifestations of arthropathy.⁶

According to International Society of Thrombosis and Hemostasis (ICTH) definitions, primary prophylaxis begins in the absence of documented joint disease and before the second clinically evident joint bleed and before the age of three years. Secondary prophylaxis commences after two or more joint bleeds. Once joint disease appears prophylaxis needs modifications. Tertiary prophylaxis is defined as treatment initiation after the onset of joint disease at any age of patient.⁶⁻⁹

Current approaches improving prophylaxis outcomes include best use of availability of factor concentrate and

Authorship Contribution: ^{1,2}Conceived and planned the idea of the study, Collecting the data, ²drafting the work or revising it critically for important intellectual content,^{2,3} Active participation in active methodology

²final approval of the version to be published,

Funding Source: none

Conflict of Interest: none

Received: Aug 27, 2024

Accepted: Nov 29, 2024

individualization of treatment regimens with respect to dose intervals, and type of concentrate, considering trough levels and bleeding triggers.^{6,10} World Federation of Haemophilia (WFH) recommends short-term intermittent prophylaxis for patients with moderate or severe haemophilia A or B and who experienced a life-threatening bleed, such as intracranial haemorrhage.¹¹

Lack of appropriate treatment for recurrent bleeding results in intra-articular changes that culminate in progressive joint destruction, irreversible arthropathy, chronic pain and overall deterioration of disability. Loss of opportunities, school absenteeism, frequent hospital visits, poor quality of life (QoL), stress and economic burden are other drawbacks associated with the disease.^{4,11,12}

Methodology

Twenty-one patients with severe Haemophilia A, registered with Haemophilia Treatment Centre Rawalpindi, were enrolled in the study. According to Low Dose Prophylaxis (LDP) protocol, patients were started on a uniform dose of extended half life, recombinant, Factor VIII concentrate (Eloctate), 250 IU, intravenous, once weekly, escalated to twice weekly if a patient experienced more than two spontaneous bleeds in three months, and thrice weekly if bleeding continued after initial dose escalation. Eleven patients were on once weekly, nine on twice weekly and one thrice weekly infusions. Low dose prophylaxis dose per Kg of body weight per week was calculated by multiplying the number of times the dose was given in a week with 250 IU and the result divided by the body weight in Kg.

Twenty-one patients, receiving episodic treatment were also included. Inferential statistics (Mann-Whitney test) was applied to compare prophylactic group with and on-demand group. Primary outcome was the total spontaneous bleeds; Secondary outcome was presence of factor VIII inhibitors. All the children were assessed every four months for spontaneous bleeds. Inhibitors were screened in serum six monthly. Patients were followed for twenty four months and Annualized Bleeding Rate (ABR) was calculated. This study was sponsored by World Blood Diseases Registry (WBDR) grant. Factor concentrates were donated by World Federation of Haemophilia (WFH) Aid Program.

Results

Mean Annualized Bleeding Rate (ABR), during study period was 0.07, which is significantly less as compared to episodic treatment group. Development of inhibitors was not found in any patient on prophylactic treatment. Occurrence of bleeding episodes was also significantly less as compared to those who were on episodic treatment (Table I). Age range was two to nine years (mean 4.07 years). To compare inhibitors production between two groups, exact binomial test was applied, which revealed a significant difference between both groups. The incidence of inhibitor formation in the group given Factor VIII on demand is 1 out of 21, which is approximately 4.76%. In contrast, in the group given Factor VIII eight as prophylaxis, there were no reported cases of inhibitor formation. (Table II)

Table I: Low Dose Prophylaxis in Haemophilia- Treatment outcome.

Variable	Prophylactic Group (n=22)	Episodic treatment Group (n=22)	p-value
Mean Annualized Bleeding rate (ABR)	0.07	6.0	<0.001*
Inhibitor production	Nil	3.5%	
Patients without bleeding	22/24	Nil	<0.0001*

Table II: Inhibitors in low dose prophylaxis versus on demand therapy patients. (Binomial Test of Proportions)

		Category	N	Observed Prop.	Test Prop.	Exact Sig. (2-tailed)
Inhibitor	Group 1	developed	1	0.05	0.50	0.000
	Group 2	None	41	0.95		
	Total		42	1.00		
Factor 8	Group 1	On-demand	21	0.51	0.50	1.000
	Group 2	Prophylaxis	21	0.49		
	Total		42	1.00		

Discussion

Episodic treatment (ET) can terminate bleeding, alleviate pain and re-establish joint mobility, but unlikely to avert arthropathy.¹³ Now, prophylactic treatment (PT) is

considered as optimal care for haemophilia patients to prevent bleeding and to preserve joint function.^{5,14} For patients with haemophilia with severe phenotype (many patients with moderate haemophilia with a severe phenotype), the WFH recommends prophylactic treatment.⁹

Prophylaxis with acceptable results needs to be initiated very early (≤ 36 months).^{15,16} Studies reported a significant decline in risk of joint damage in children under prophylaxis, receiving recombinant factor VIII concentrates versus children under intensive episodic treatment.^{17,18} Several trials on prophylaxis have shown that it effectively prevents recurrent joint bleeding which would lead to arthropathy and disability, compared to on-demand treatment.^{2,4,10,11,13,17-25} With optimized prophylaxis the expected outcome is that children with hemophilia will reach adulthood with normal joint function and live a full and active life in the absence of bleeding events.^{9,12}

Low Dose Prophylaxis (L.D.P) has been developed as a solution to minimize these challenges and to provide better care for subjects with haemophilia from low resource countries. The impact of L.D.P is evaluated in several studies. LDP regimens, in patients with severe haemophilia A, with a dose of 10 to 15 IU/kg, 1 or 2 times per week, ensure better outcomes. Studies reported acceptable results in majority (85%), even with factor levels low than 1%. Recognized benefits of lower dose infusion frequency are fewer clinic visits, less need for CAVADs, less burdensome infusion schedules (dosing, days and times), fewer infusions on work/school days and many others. This allows replacement therapy with annual consumption similar to episodic treatment but with a much lower rate of spontaneous bleeds.^{3,4,9,22,26-31-34}

Studies comparing episodic with prophylactic therapy in haemophilia A revealed that approximately thirty to forty percent of patents in episodic group were hospitalized during study period, as compared to that none in prophylactic group. Studies also demonstrated a significant reduction in the total number of bleeding episodes, joint bleeds and improvement in joint function in low-dose prophylaxis group, as compared to porophylactic group.^{14,17,18,32}

Canadian Hemophilia Primary Prophylaxis Study (CHPS) was pioneer in tailoring prophylaxis and was able to produce adequate preservation of joint status using less factor.³⁵ In patients on prophylactic therapy regimens

Total Gilbert Joint Scores improves better, as compared with on-demand therapy, and is likely to eliminate surgical/orthopedic intervention which may be required in long run.^{9,36} Better treatment adherence is also witnessed in paediatric prophylactic groups, as parents follow regimens of children more regularly. The adults, being independent in many ways, show less adherence.^{1,37-39}

In long-acting F-VIII concentrates fusion of biologically active protein, to Fc domain of human IgG, facilitates binding of the protein to the neonatal Fc receptor (Fc-Rn). This Fc-Rn is expressed in many cell types throughout life. Once the Fc-fusion protein binds to Fc-Rn, it becomes protected from lysosomal degradation. When Fc-fusion proteins and IgG are taken up from circulation into cells by endocytosis, they interact with Fc-Rn endosomes and are redirected back to plasma. This naturally occurring recycle pathway prolongs the half lives of various biologics, including recombinant F-VIII. Similar extended half-life products are now under study with PEGylation of recombinant F-VIII.^{40,41} Currently there are four main EHL Factor-VIII therapies available, which can be categorized into two main groups i.e., Fc-fusion treatments and PEGylated (conjugation of F-VIII proteins with polyethylene glycol (PEG) treatments. Ultra low F- VIII replacement therapies are also in development, but their impact on the treatment landscape remain to be seen.⁴⁰⁻⁴⁴

A wide variability is reported even in developed world for the availability of primary PT. Clotting factor concentrates cost appears to be the crucial barrier in this regard. Even in United States of America approximately 19% of children receive primary prophylaxis and a wide variability is reported.^{3,45}

It is required to explore pharmacokinetics and acceptable trough levels, as studies reveal adequate bleeding control even at a low level.^{38-40,46} Using longer-acting coagulation factors with different pharmacokinetic profiles is likely to further individualize treatment by maintaining adequate trough levels with fewer infusions.⁶ Genotypically different mutations, most importantly F8/F9 gene mutations, splice site mutations and some small deletions, can be held responsible for a disease phenotype, with reduced frequency of spontaneous bleeds. Analysis revealed that specific cohort of patients

can have a non-bleeding status even with low factor level.^{5,6,31,40}

In present study none of the patients developed inhibitors against F-VIII. Most of the studies substantiate this finding.^{24,47} Evidence shows that 95% of inhibitor occurrence is in the first fifty exposure days. Limited factor exposure in prophylactic regimens can be assumed as a factor for low inhibitor occurrence in haemophiles on prophylactic regimens.^{6,9,22,24,40}

It is widely accepted that keeping trough levels about 1% should be a minimum, as few joint bleeds occur about this level. The mean F-VIII used during prophylaxis is found to be lower as compared to the on-demand arm, though not significant statistically. But, it translates into overall reduction in cost of therapy in long run.^{5,40,48}

Individual dosing based on differences in pharmacokinetic handling of coagulation factors has the potential to optimize clinical efficacy of these expensive therapies. Time spent in a therapeutic window or a 'normal' and safe zone between trough and peak thresholds, are now regarded as important concepts to define effective prophylactic regimens for individual patients.^{12,30} PK parameter such as incremental recovery area under the concentration – time curve (AUC), clearance (CL) and subsequently $t_{1/2}$ are now considered surrogate efficacy endpoints for F-VIII replacement therapies.¹² There is a significant variation between patient's coagulation factor pharmacokinetics.. Wide inter-patient variability in PK, lifestyle and physical activity levels, the ability to adjust F-VIII levels and to provide appropriate bleeding protection to suit a given situation may be crucial factor in the treatment decision – making process.^{37,46}

Conclusion

1. Low dose prophylaxis, in haemophilia, is cost-effective, efficient and safe method for preventing joint bleeds and hence delaying joint damage.
2. Adherence to treatment recommendations and follow up is an ongoing challenge, common to long term medical conditions, like haemophilia.
3. Long acting recombinant Factor VIII concentrates (with extended half-life). It makes possible prophylaxis-adherence an achievable goal, even in financially-constrained set up.

4. Prophylactic regimens can achieve a non-bleeding status even with low trough levels of factors
5. Particular attention is required to tailor individual treatment regimens in accordance to pharmacokinetics of factor, preferred life style and daily physical activities, including sports
6. Central to the success of prophylaxis are clinics with comprehensive care that provide the necessary professional expertise, support and counselling, to educate patients, families and other health care professionals, and to support research for improved haemophilia care.

References

1. Sun J, Zhou X, Hu N. Factor VIII replacement prophylaxis in patients with haemophilia A-transitioning to adults. *Orphanet J Rare Dis.* 2021;16(267). Available from: <https://doi.org/10.1186/s13023-021-01919-w>
2. Castaman G, Rocino A, Mazzucconi MG, Zanoni E. Prophylaxis therapy in paediatric patients with haemophilia A. *Blood Transfus.* 2015;13(8):631-8.
3. Sidharthan N, Sudeven R. Low dose prophylaxis in hemophilia care. *Indian J Hematol Blood Transfus.* 2022;36(1):16-25. Available from: <https://doi.org/10.1007/s12288-019-01147-0>
4. Yao W, Xiao J, Cheng X, Feng G, Li C. The efficacy of recombinant factor VIII low-dose prophylaxis in Chinese paediatric patients. *Clin Appl Thromb Hemost.* 2017;23(7):851-8. Available from: <https://doi.org/10.1177/1076029616679507>
5. Poon MC, Lee A. Individualized prophylaxis for optimizing hemophilia care: Can we apply this to both developed and developing nations? *Thromb J.* 2016;14(1). Available from: <https://doi.org/10.1186/s12959-016-0096-y>
6. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. *Blood.* 2015;125(13):2038-44. Available from: <https://doi.org/10.1182/blood-2015-01-528414>
7. Blanchette VS, Key NS, Ljung LR, Manoo Johnson MJ. Subcommittee on factor VIII, factor IX and rare coagulation disorders. Definitions in haemophilia: communication for the SSC of ISTH. *J Thromb Haemost.* 2014;12(11):1935-9. Available from: <https://doi.org/10.1111/jth.12672>
8. Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M. WFH guidelines for the management of hemophilia, 3rd ed. *Haemophilia.* 2020;26:1-158. Available from: <https://doi.org/10.1111/hae.14046>
9. Carcao M, Vanden Berg HM, Gouider EG, Khair K. Prophylaxis in hemophilia - Guidelines for the management of hemophilia. *World Federation of Hemophilia.* 3rd ed. 2020;81-92.
10. Dutta TK. Low dose factor VIII prophylaxis in hemophilia: Indian perspective. *Hematol Int J.* 2021;5(2):00190. Available from: <https://doi.org/10.23880/hij-16000190>
11. Chozie NA, Primackti F, Saraswati MC, Sekarasari D. Short-term intermittent prophylaxis post-intracranial hemorrhage in children with haemophilia. *Paediatr Indones.* 2022;62(3):174-8. Available from: <https://doi.org/10.14238/pi62.3.2022.174-9>
12. Bentor E, Hermans C, Solms A, Poulsen L, Monocuso ME. Optimizing prophylaxis in hemophilia A: The ups and downs of

- treatment. *Blood Rev.* 2021;100852. Available from: <https://doi.org/10.1016/j.blre.2021.100852>
13. Sidharthan N, Sudevan R, Narayana V, Mathew S, Raj M. Low-dose prophylaxis for children with haemophilia in a resource-limited setting in South India. *Haemophilia.* 2017;23:e382-4. Available from: <https://doi.org/10.1111/hae.13272>
14. Shetty S, Bansal S, Kshiragar S, Rangarayan S, Hajirni K. Low dose prophylaxis and its impact on the health of haemophilia patients. *Vox Sang.* 2022;117(7):900-12. Available from: <https://doi.org/10.1111/vox.13278>
15. Gringeri A, Lundin B, Mackensen SV, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with haemophilia (ESPRIT Study). *J Thromb Haemost.* 2011;9(4):700-10. Available from: <https://doi.org/10.1111/j.1538-7836.2011.04214.x>
16. Witmer C, Presley R, Kulkarni R, Manno CS, Raffini L. Association between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. *Br J Haematol.* 2010. Available from: <https://doi.org/10.1111/j.1365-214>
17. Manoo-Johnson MJ, Abshire TC, Shapiro AD. Prophylactic versus episodic treatment to prevent joint disease in boys with severe hemophilia. *Joint Outcome Study.* *N Engl J Med.* 2007;357(6):535-44.
18. Singh A, Menta S, Goyal LK, Menta S, Sharma BS. Low dose prophylaxis vis-à-vis on-demand treatment strategies for haemophilia: A cost-effective and disability-attenuating approach. *J Assoc Physicians India.* 2019.
19. Gouider E. Show me the evidence: Effectiveness of low dose prophylaxis. *Haemophilia.* 2019;26:9-10. Available from: <https://doi.org/10.1111/hae.13892>
20. Tang L, Wu R, Sun J, Zhang X, Feng X. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleeds and improve daily activity. *Haemophilia.* 2013;19:27-34. Available from: <https://doi.org/10.1111/j.1365-2516.2012.02926.x>
21. Verma SP, Dutta TK, Mahadevan S, Nalini P, Basu P. A randomized study of very low dose factor VIII prophylaxis in severe haemophilia. *Haemophilia.* 2016;22(3):342-4. <https://doi.org/10.1111/hae.12838>
22. Esghani P, Sadeghi E, Tara SZ, Habibpanah B. Iranian low dose escalating prophylaxis regimens in children with severe haemophilia A and B. *Thromb Haemost.* 2018;24(3):513-8. <https://doi.org/10.1177/1076029616685429>
23. De D, Datta SS, Basal B, Halder S. Very low dose prophylaxis in children with haemophilia: a rural Indian experience. *EHA Library.* 2018;215843:S890.
24. Valentino LA, Mamon V, Helmann A, Quon DV, Chybicka A. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. *J Thromb Haemost.* 2011;10(2):359-67. <https://doi.org/10.1111/j.1538-7836.2011.04611.x>
25. Ponnoose P. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage-the MUSFIH Study. *Haemophilia.* 2017;3(4):538-46. <https://doi.org/10.1111/hae.13242>
26. Feldman BM, Pai M, Rivard GE. Tailored prophylaxis in severe haemophilia A. Interim results from the first 5 years of Canadian Hemophilia Primary Prophylaxis Study. *J Thromb Haemost.* 2006;4(6):1228-36. <https://doi.org/10.1111/j.1538-7836.2006.01953.x>
27. Rangi MV, Fogarty PJ, Josephson NC, Neff AT, Raffini LJ. Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in U.S haemophilia treatment centres. *Haemophilia.* 2012;18(1):63-8. <https://doi.org/10.1111/j.1365-2516.2011.02554.x>
28. Nijdam A, Kurnik K, Leisner R. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. *Haemophilia.* 2015;21(4):444-50. <https://doi.org/10.1111/hae.12613>
29. Kurnik K, Bidlingmaier C, Engi IW, Chehadeh H, Reipert B. New early prophylaxis regimen that avoids immunological danger signals can reduce F-VIII inhibitor development. *Haemophilia.* 2010;16(2):256-62. <https://doi.org/10.1111/j.1365-2516.2009.02122.x>
30. Esghi P, Sadeghi E, Tara SZ, Habibpannah E, Hantooshzadah R. Iranian low-dose escalating prophylaxis regimens in children with severe hemophilia. *Clin Appl Thromb Hemost.* 2017;24:513-8. <https://doi.org/10.1177/1076029616685429>
31. Dargandi Y, Delavenne X, Hart DP, Meunier S. Pharmacokinetic-based prophylaxis in severe haemophilia. *Haemophilia.* 2018;24(Suppl 2):3-17. <https://doi.org/10.1111/hae.13397>
32. Ali RM, Abid M, Zafar S, Ali MS, Nadeem R, Borhany M. Management of severe hemophilia A: Low-dose prophylaxis vs. on-demand treatment. *Cureus.* 2023;15(7):e41410. <https://doi.org/10.1016/j.rpth.2023.101094>
33. Molho P, Rolland N, Lebrun I, Dirat G, Courpied JP. Epidemiological survey of orthopedic status of severe haemophilia A and B patients in France. *Haemophilia.* 2000;23:23-32. <https://doi.org/10.1046/j.1365-2516.2000.00358.x>
34. Gouider E, Jouini L, Achour M, Elmahmoudi H, Zahara K, Said W. Low dose prophylaxis in Tunisian children with haemophilia. *Haemophilia.* 2017;23(1):77-81. <https://doi.org/10.1111/hae.13048>
35. Bianchette V, Israel S, Chan A, Rivard G, Cloutier S. Fifteen years of Canadian "tailored" prophylaxis: results from the Canadian Haemophilia Primary Prophylaxis Study (C.H.P.S.). *Haemophilia.* 2014;20(Suppl):394-8.
36. Collins P, Faradi A, Morfini M, Enriquez MM. Efficacy and safety of secondary prophylactic versus on-demand low-dose formulated recombinant factor VIII treatment in adults with severe haemophilia A. *J Thromb Haemost.* 2010;8(1):83-9. <https://doi.org/10.1111/j.1538-7836.2009.03650.x>
37. Barnes C. Importance of pharmacokinetics in the management of haemophilia. *Pediatr Blood Cancer.* 2013;60(Suppl 1):27-9. <https://doi.org/10.1002/pbc.24339>
38. Tezanos Pinto M. Haemophilia in the developing world: successes, frustrations and opportunities. *Haemophilia.* 2004;10(4):14-9. <https://doi.org/10.1111/j.1365-2516.2004.00986.x>
39. Collin PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, Fritsch S. Breakthrough bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. *J Thromb Haemost.* 2009;7:413-20. <https://doi.org/10.1111/j.1538-7836.2008.03270.x>
40. Mandal PK, Phukan A, Bhowmik A, Gautam D. Effect of tertiary prophylaxis with low-dose factor VIII on quality of life in adult patients with severe haemophilia A. *J Appl Hematol.* 2022;119:88-93. https://doi.org/10.4103/joah.joah_37_19